ADHD drug developer and manufacturer Neos Therapeutics has filed a price range of $14 to $16 for its upcoming IPO, which would raise $60 million if priced at the range midpoint. A portion of the proceeds from the offering will go to fund the pre-commercialization planning and commercialization of Neos's three lead product candidates. The company, which has raised more than $98 million to date, collected $21 million at a valuation of $116 million in its most recent funding in February. Current shareholders include Burrill Life Sciences (13.15% pre-IPO stake) and Presidio Ventures (12.97%). Neos plans to list shares on the NASDAQ under the symbol NEOS.